Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years  Areej El-Jawahri, Shuli Li, Joseph.

Slides:



Advertisements
Similar presentations
A disease risk index for patients undergoing allogeneic stem cell transplantation by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T. Ho,
Advertisements

Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD by Ana C. Alho, Haesook T.
High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma (PCNSL) in First Complete Remission (CR1) 
Cord-Blood Hematopoietic Stem Cell Transplant Confers an Increased Risk for Human Herpesvirus-6-Associated Acute Limbic Encephalitis: A Cohort Analysis 
In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,
Immune Reconstitution after Double Umbilical Cord Blood Stem Cell Transplantation: Comparison with Unrelated Peripheral Blood Stem Cell Transplantation 
Autologous Stem Cell Transplantation with Thiotepa, Busulfan, and Cyclophosphamide (TBC) Conditioning in Patients with CNS Involvement by Non-Hodgkin.
Graft-Versus-Host Disease and Survival after Cord Blood Transplantation for Acute Leukemia: A Comparison of Japanese versus White Populations  Yachiyo.
Biology of Blood and Marrow Transplantation
Bradley W. Blaser, Haesook T. Kim, Edwin P. Alyea, Vincent T
Prediction of Veno-Occlusive Disease Using Biomarkers of Endothelial Injury  Corey Cutler, Haesook T. Kim, Shaké Ayanian, Gary Bradwin, Carolyn Revta,
by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T
Daniela Ion, Kristen Stevenson, Sook-Bin Woo, Vincent T
A Phase II Study of Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft- versus-Host Disease  Alex F. Herrera, Haesook T. Kim, Bhavjot Bindra,
Hematopoietic Cell Transplantation with and without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1  Andrew M. Brunner,
Allogeneic Transplantation with Reduced-Intensity Conditioning for Hodgkin and non- Hodgkin Lymphoma: Importance of Histology for Outcome  Philippe Armand,
Phase I Study of Urate Oxidase in the Reduction of Acute Graft-Versus-Host Disease after Myeloablative Allogeneic Stem Cell Transplantation  Albert C.
Sonidegib (LDE-225), a Sonic Hedgehog Pathway Inhibitor, for the Treatment of Steroid- Refractory Chronic Graft-Versus-Host Disease  Zachariah DeFilipp,
Childhood Obesity and Outcomes after Bone Marrow Transplantation for Patients with Severe Aplastic Anemia  Collin C. Barker, Manza-A. Agovi, Brent Logan,
Comparison of Different Rabbit Anti-Thymocyte Globulin Formulations in Allogeneic Stem Cell Transplantation: Systematic Literature Review and Network.
Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation.
Outcome and Prognostic Factors for Patients Who Relapse after Allogeneic Hematopoietic Stem Cell Transplantation  Gita Thanarajasingam, Haesook T. Kim,
Nienke M. G. Rorije, Margaret M. Shea, Gowri Satyanarayana, Sarah P
Busulfan Dose Intensity and Outcomes in Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation for Myelodysplastic Syndrome or Acute.
Impact of Age on Quality of Life, Functional Status, and Survival in Patients with Chronic Graft-versus-Host Disease  Areej El-Jawahri, Joseph Pidala,
Pretransplantation Supportive and Palliative Care Consultation for High-Risk Hematopoietic Cell Transplantation Patients  Elizabeth T. Loggers, Thomas.
Jennifer Crombie, Laura Spring, Shuli Li, Robert J. Soiffer, Joseph H
Low Relapse without Excessive Transplant-Related Mortality following Myeloablative Cord Blood Transplantation for Acute Leukemia in Complete Remission:
Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation  Philippe Armand, Haesook T. Kim, Daniel.
Seroprotective Titers against 2009 H1N1 Influenza A Virus after Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Recipients  Nicolas.
Phase II Trial of Parathyroid Hormone after Double Umbilical Cord Blood Transplantation  Karen Ballen, Adam M. Mendizabal, Corey Cutler, Ioannis Politikos,
Trial in Progress: Gravitas-301, a Randomized, Double-Blind Phase 3 Study of Itacitinib or Placebo with Corticosteroids (CS) for the First-Line Treatment.
Oral Chronic Graft-versus-Host Disease Scoring Using the NIH Consensus Criteria  Nathaniel S. Treister, Kristen Stevenson, MS, Haesook Kim, Sook-Bin Woo,
Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute.
Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome  Haesook T. Kim, Philippe Armand,
Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation.
Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma  John Kuruvilla, Gregory Pond, Richard.
Risk Factors for Invasive Fungal Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Single Center Experience  Aazim K. Omer, Panayiotis.
Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell– Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous.
Post-Transplantation B Cell Activating Factor and B Cell Recovery before Onset of Chronic Graft-versus-Host Disease  Caron A. Jacobson, Lixian Sun, Haesook.
Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma:
Efficacy of Thiotepa-Busulfan-Cyclophosphamide (TBC) Conditioning and Autologous Transplantation As Consolidation for Systemic Non-Hodgkin Lymphoma with.
An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease 
Prognostic Understanding, Quality of Life, and Mood in Patients Undergoing Hematopoietic Stem Cell Transplantation  Areej El-Jawahri, MD, Lara Traeger,
Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and Mini-Methotrexate (Tac/Sir/MTX) as Acute Graft-versus-Host Disease.
Mucositis after Allogeneic Hematopoietic Stem Cell Transplantation: A Cohort Study of Methotrexate- and Non-Methotrexate-Containing Graft-versus-Host.
Allogeneic Stem Cell Transplantation for Aplastic Anemia
Akiko M. Saito, Corey Cutler, David Zahrieh, Robert J
Merve Postalcioglu, Haesook T. Kim, Faruk Obut, Benjamin C
Low-Dose IL-2 Therapy Preferentially Improves Diversity of the Regulatory T Cell Repertoire in Patients with Refractory Chronic Graft-Versus-Host Disease 
What is quality in a transplant program?
The Impact of Geographic Proximity to Transplant Center on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation  Karim E. Abou-Nassar, Haesook.
Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: Hematologic Malignancy Outcomes Are Not Impaired in Advanced.
Recovery of Circulating T-Follicular Helper Cells after Hematopoietic Stem Cell Transplantation  Edouard Forcade, MD, Steven Paula, Kristen Cowens, Marta.
A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality  Margaret.
Karen K. Ballen, Thomas R. Spitzer, Beow Y
Blood and Marrow Transplant Handbook
A Prognostic Score for Patients with Acute Leukemia or Myelodysplastic Syndromes Undergoing Allogeneic Stem Cell Transplantation  Philippe Armand, Haesook.
A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation:
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Prediction and prevention of transplant-related mortality from pulmonary causes after total body irradiation and allogeneic stem cell transplantation 
Treatment versus Transplant for Challenging Hematologic Disorders
Reduced-Intensity Conditioning Stem Cell Transplantation: Comparison of Double Umbilical Cord Blood and Unrelated Donor Grafts  Yi-Bin Chen, Julie Aldridge,
Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human.
Sarah Nikiforow, Haesook T
Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?
In Memoriam: E. Donnall Thomas
Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience  Andy I. Chen, Alex McMillan,
Iron Overload in Patients with Acute Leukemia or MDS Undergoing Myeloablative Stem Cell Transplantation  Philippe Armand, Haesook T. Kim, Joanna Rhodes,
Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation  Lindsey E.
Presentation transcript:

Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years  Areej El-Jawahri, Shuli Li, Joseph H. Antin, Thomas R. Spitzer, Philippe A. Armand, John Koreth, Sarah Nikiforow, Karen K. Ballen, Vincent T. Ho, Edwin P. Alyea, Bimalangshu R. Dey, Steven L. McAfee, Brett E. Glotzbecker, Robert J. Soiffer, Corey S. Cutler, Yi-Bin Chen  Biology of Blood and Marrow Transplantation  Volume 22, Issue 5, Pages 910-918 (May 2016) DOI: 10.1016/j.bbmt.2015.12.024 Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 TRM (P = .0002), PFS (P = .0002), and OS (P = .0003) in patients with overall grade III and IV acute GVHD. Biology of Blood and Marrow Transplantation 2016 22, 910-918DOI: (10.1016/j.bbmt.2015.12.024) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 TRM (P = .21), PFS (P = .97), and OS (P = .90) in patients with overall grade III acute GVHD. Biology of Blood and Marrow Transplantation 2016 22, 910-918DOI: (10.1016/j.bbmt.2015.12.024) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 TRM (P = .002), PFS (P < .0001), and OS (P = .0003) in patients with overall grade IV acute GVHD. Biology of Blood and Marrow Transplantation 2016 22, 910-918DOI: (10.1016/j.bbmt.2015.12.024) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.